<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: EMR and ablation are increasingly being used alone or in combination for treatment of Barrett's <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Given a very low rate of lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, endotherapy has become an accepted treatment option for T1a esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC) with low-risk features </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To report our experience of endoscopic management of T1a EAC in a large, tertiary-care center </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Retrospective review </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Tertiary-care referral center </plain></SENT>
<SENT sid="5" pm="."><plain>PATIENTS: Patients treated endoscopically for low-risk T1a EAC at our center </plain></SENT>
<SENT sid="6" pm="."><plain>INTERVENTION: EMR and endoscopic ablation </plain></SENT>
<SENT sid="7" pm="."><plain>MAIN OUTCOME MEASUREMENTS: <z:hpo ids='HP_0011420'>Death</z:hpo> related to <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, remission of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: A total of 54 patients underwent endotherapy for low-risk T1a EAC from 2006 to 2012 </plain></SENT>
<SENT sid="9" pm="."><plain>Mean (± SD) follow-up was 23 (± 16) months, mean (± SD) size of resected <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> was 7.1 (± 4.3) mm, and mean (± SD) <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> length was 4.5 (± 3.9) cm </plain></SENT>
<SENT sid="10" pm="."><plain>Band-assisted, cap-assisted, and lift and cut EMR were performed in 85%, 11%, and 4% of patients, respectively; 81% underwent additional ablative therapy (radiofrequency ablation 95%, cryotherapy 9%, photodynamic therapy 2%) </plain></SENT>
<SENT sid="11" pm="."><plain>Complete remission from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was achieved in 96%, complete remission from <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in 87%, and complete remission from <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> in 59% </plain></SENT>
<SENT sid="12" pm="."><plain>The overall survival was 89%; there were no <z:hpo ids='HP_0011420'>deaths</z:hpo> related to <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>LIMITATIONS: Retrospective study </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Endotherapy for T1a EAC was safe and effective in our American cohort </plain></SENT>
<SENT sid="15" pm="."><plain>Endotherapy should be considered primary therapy for appropriate patients with low-risk lesions </plain></SENT>
<SENT sid="16" pm="."><plain>Complete <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> eradication after EMR is important to reduce the development of metachronous lesions </plain></SENT>
</text></document>